1. Home
  2. BOE vs RIGL Comparison

BOE vs RIGL Comparison

Compare BOE & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOE
  • RIGL
  • Stock Information
  • Founded
  • BOE 2005
  • RIGL 1996
  • Country
  • BOE United States
  • RIGL United States
  • Employees
  • BOE N/A
  • RIGL N/A
  • Industry
  • BOE Trusts Except Educational Religious and Charitable
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • BOE Finance
  • RIGL Health Care
  • Exchange
  • BOE Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • BOE 643.8M
  • RIGL 537.6M
  • IPO Year
  • BOE N/A
  • RIGL 2000
  • Fundamental
  • Price
  • BOE $11.52
  • RIGL $50.83
  • Analyst Decision
  • BOE
  • RIGL Strong Buy
  • Analyst Count
  • BOE 0
  • RIGL 5
  • Target Price
  • BOE N/A
  • RIGL $43.20
  • AVG Volume (30 Days)
  • BOE 166.1K
  • RIGL 756.5K
  • Earning Date
  • BOE 01-01-0001
  • RIGL 11-04-2025
  • Dividend Yield
  • BOE 7.30%
  • RIGL N/A
  • EPS Growth
  • BOE N/A
  • RIGL 2698.26
  • EPS
  • BOE N/A
  • RIGL 6.20
  • Revenue
  • BOE N/A
  • RIGL $282,076,000.00
  • Revenue This Year
  • BOE N/A
  • RIGL $59.93
  • Revenue Next Year
  • BOE N/A
  • RIGL N/A
  • P/E Ratio
  • BOE N/A
  • RIGL $8.00
  • Revenue Growth
  • BOE N/A
  • RIGL 79.13
  • 52 Week Low
  • BOE $8.80
  • RIGL $14.63
  • 52 Week High
  • BOE $10.48
  • RIGL $50.23
  • Technical
  • Relative Strength Index (RSI)
  • BOE 54.19
  • RIGL 73.43
  • Support Level
  • BOE $11.10
  • RIGL $34.00
  • Resistance Level
  • BOE $11.40
  • RIGL $50.23
  • Average True Range (ATR)
  • BOE 0.13
  • RIGL 3.04
  • MACD
  • BOE 0.01
  • RIGL 1.10
  • Stochastic Oscillator
  • BOE 80.91
  • RIGL 97.03

About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest

Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: